Prof Alexander Eggermont, President of the European CanCer Organisation, talks to Editor Gordon McVie about a new era of melanoma treatment, immunomodulation, combination immunotherapy, ipilimumab's unprecedented success in increasing the 2 year survival rate, the EORTC 18071 trial, BRAF mutations, ECCO's lifetime achievement award and his initiative of 'oncopolicy'.